Back to Search Start Over

Public Interest in COVID-19 Therapeutics for High-Risk Populations During the Omicron Era: A Google Trends Analysis.

Authors :
Degirmenci HB
Oh J
Bays AM
Thomason JL
Liew JW
Source :
Cureus [Cureus] 2022 Dec 19; Vol. 14 (12), pp. e32684. Date of Electronic Publication: 2022 Dec 19 (Print Publication: 2022).
Publication Year :
2022

Abstract

Therapies for COVID-19 prevention or treatment continue to play a significant role for individuals who are not able to mount an adequate immune response after COVID-19 vaccination and/or in patients who are at high-risk for severe outcomes of COVID-19 infection. As these modalities have become more available, it is important to assess the public's interest in these agents to ensure both patients and physicians are aware of the therapeutics available to them. Google Trends is a freely available tool that researchers can use for monitoring public interest by analyzing trends in search queries during disease outbreaks. In this descriptive study, we used Google Trends to investigate the public interest in two COVID-19 therapeutics which received Food and Drug Administration (FDA) emergency use authorization in December 2021: Paxlovid, an antiviral medication used for COVID-19 treatment, and Evusheld, a combination of two monoclonal antibodies against COVID-19 used for COVID-19 prophylaxis. We analyzed search queries in the first half of 2022. Our analysis included search queries that include ''Paxlovid'', ''Evusheld'', ''COVID treatment'' and ''COVID prophylaxis'' at the national and state levels in the US. We found that while the number of COVID-19 cases rose during the period of interest, Evusheld searches remained stagnant despite a concurrent increase in Paxlovid searches. These findings potentially represent low public interest or awareness about Evusheld, which can be addressed through public health initiatives to ensure improved distribution.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright © 2022, Degirmenci et al.)

Details

Language :
English
ISSN :
2168-8184
Volume :
14
Issue :
12
Database :
MEDLINE
Journal :
Cureus
Publication Type :
Academic Journal
Accession number :
36660525
Full Text :
https://doi.org/10.7759/cureus.32684